Skip to main content

Advertisement

SpringerLink
Log in

Stromal Caveolin-1 Expression in Breast Carcinoma. Correlation with Early Tumor Recurrence and Clinical Outcome

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Caveolin- (cav-1) has been linked to tumor progression and clinical outcome in breast cancer, but its role as a prognostic marker is still unclear. We evaluated stromal and tumor caveolin-1 expression in 91 breast carcinomas, and assessed the association between their expression and clinicopathologic variables as well as patient outcome and early tumor recurrence. Absence of stromal caveolin-1 expression was detected in 18.7% of cases, while 25.3% of cases revealed tumor epithelial caveolin-1 expression. Combined stromal and tumor caveolin-1 immunopositivity was seen in 24.2% of cases. Absence of stromal cav-1 associated with larger tumor size, higher grade, higher nodal stage, higher number of positive nodes, higher TNM stage, positive HER2 status, higher recurrence rate, and shorter mean progression free survival (PFS). Stromal cav-1 status was a significant predictor of PFS in ER+, PR +, and HER2 + tumors. In tamoxifen-treated patients, absence of stromal Cav-1 was a significant predictor of poor clinical outcome, suggestive of tamoxifen resistance. Conversely, tumor epithelial and combined caveolin-1 expression, didnot associate with patient outcome. In multivariate analysis, only TNM stage independently associated with survival. Loss of stromal caveolin-1 is a novel breast cancer biomarker that can predict early tumor recurrence, short PFS, and tamoxifen- resistance. Thus, its use as a predictive biomarker, especially in lower grade, lower stage, ER+, PR+, HER2+, and tamoxifen treated patients may allow for early interventions with more aggressive therapies. Thus, stromal marker expression and epithelial-stromal cross talk may be critical for tumor progression and metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Abbreviations

CAFs:

Cancer associated fibroblasts

Cav-1:

Caveolin-1

DCIS:

Ductal carcinoma in situ

FFPE:

Formalin fixed paraffin embedded

MECs:

Myoepithelial cells

PASW:

Predictive analytics software

PFS:

Progression free survival

References

  1. Liedtke C, Kersting C, Bürger H et al (2007) Caveolin-1 expression in benign and malignant lesions of the breast. World J Surg Oncol 5:110. doi:10.1186/1477-7819-5-110

    Article  PubMed  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  3. Witkiewicz AK, Dasgupta A, Sotgia F et al (2009) An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers. Am J Pathol 174:2023–34

    Article  PubMed  CAS  Google Scholar 

  4. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–7

    Article  PubMed  CAS  Google Scholar 

  5. Bissell MJ, Radisky D (2001) Putting tumors in context. Nat Rev Cancer 1:1–19

    Article  Google Scholar 

  6. Mueller MM, Fusenig NE (2004) Friends or foes—bipolar effects of the tumor stroma in cancer. Nat Rev Cancer 4:839–49

    Article  PubMed  CAS  Google Scholar 

  7. Kim JB, Stein R, O’Hare MJ (2005) Tumor-stromal interactions in breast cancer: the role of stroma in tumorigenesis. Tumour Biol 26:173–85

    Article  PubMed  Google Scholar 

  8. Sloan EK, Ciocca DR, Pouliot N et al (2009) Stromal cell expression of Caveolin-1 predicts outcome in breast cancer. Am J Pathol 174:2035–43

    Article  PubMed  CAS  Google Scholar 

  9. Olumi AF, Grossfeld GD, Hayward SW (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59:5002–11

    PubMed  CAS  Google Scholar 

  10. Serini G, Gabbiani G (1999) Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 250:273–83

    Article  PubMed  CAS  Google Scholar 

  11. Hnasko R, Lisanti MP (2003) The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 3:445–64

    Article  PubMed  CAS  Google Scholar 

  12. Koleske AJ, Baltimore D, Lisanti MP (1995) Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 92:1381–5

    Article  PubMed  CAS  Google Scholar 

  13. Fielding CJ, Fielding PE (2000) Cholesterol and caveolae: structural and functional relationships. Biochim Biophys Acta 1529:210–22

    PubMed  CAS  Google Scholar 

  14. Page DL, Jensen RA, Simpson JF (1998) Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat 51:195–208

    Article  PubMed  CAS  Google Scholar 

  15. Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):966–78

    PubMed  CAS  Google Scholar 

  16. Ellis IO, Elston CW (2006) Histologic grade (chapter 19). In: O’Malley FP, Pinder SE (eds) Breast Pathology. Elsevier, Philadelphia, PA, pp 225–33

    Google Scholar 

  17. Savage K, Lambros MB, Robertson D et al (2007) Caveolin-1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 13:90–101

    Article  PubMed  CAS  Google Scholar 

  18. Allred DC, Harvey JM, Berardo M et al (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–68

    PubMed  CAS  Google Scholar 

  19. Ellis IO, Bartlett J, Dowsett M et al (2004) Best Practice No. 176: Updated recommendation for HER-2 testing in the UK. J Clin Pathol 57:322–7

    Google Scholar 

  20. Williams TM, Medina F, Badano I et al (2004) Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 279:51630–46

    Article  PubMed  CAS  Google Scholar 

  21. Elsheikh SE, Green AR, Rakha EA et al (2008) Caveolin-1 and Caveolin- 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 99:327–34

    Article  PubMed  CAS  Google Scholar 

  22. Li T, Sotgia F, Vuolo MA et al (2006) Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 168:1998–2013

    Article  PubMed  CAS  Google Scholar 

  23. Sagara Y, Mimori K, Yoshinaga K et al (2004) Clinical significance of Caveolin-1, Caveolin-2 and HER-2/neu mRNA expression in human breast cancer. Br J Cancer 91:959–65

    PubMed  CAS  Google Scholar 

  24. Hurlstone AF, Reid G, Reeves JR et al (1999) Analysis of the Caveolin-1 gene at human chromosome 7q31.1 in primary tumors and tumor-derived cell lines. Oncogene 18:1881–90

    Article  PubMed  CAS  Google Scholar 

  25. Engelman JA, Lee RJ, Karnezis A et al (1998) Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273:20448–55

    Article  PubMed  CAS  Google Scholar 

  26. Lee SW, Reimer CL, Oh P et al (1998) Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16:1391–7

    Article  PubMed  CAS  Google Scholar 

  27. Yang G, Truong LD, Timme TL et al (1998) Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4:1873–80

    PubMed  CAS  Google Scholar 

  28. Galbiati F, Volonte D, Brown AM et al (2000) Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 275:23368–77

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

All technicians at Pathology Department, Alexandria Faculty of Medicine, Egypt.

Author information

Authors and Affiliations

  1. Departement of Pathology, Alexandria Faculty of Medicine, Alexandria, Egypt

    Saba Mohamed El-Gendi

  2. Departement of Clinical Oncology, Alexandria Faculty of Medicine, Alexandria, Egypt

    Mohamed Farouk Mostafa

  3. Departement of General Surgery, Alexandria Faculty of Medicine, Alexandria, Egypt

    Ahmed Mohamed El-Gendi

  4. 29 Fawzy Moaaz Street, Smouha, Alexandria, Egypt

    Saba Mohamed El-Gendi

Authors
  1. Saba Mohamed El-Gendi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Farouk Mostafa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed Mohamed El-Gendi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saba Mohamed El-Gendi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Gendi, S.M., Mostafa, M.F. & El-Gendi, A.M. Stromal Caveolin-1 Expression in Breast Carcinoma. Correlation with Early Tumor Recurrence and Clinical Outcome. Pathol. Oncol. Res. 18, 459–469 (2012). https://doi.org/10.1007/s12253-011-9469-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-011-9469-5

Keywords

Search

Navigation